Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression.

Bruno A, Mortara L, Baci D, Noonan DM, Albini A.

Front Immunol. 2019 Apr 18;10:771. doi: 10.3389/fimmu.2019.00771. eCollection 2019. Review.

2.

Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects.

Bassani B, Baci D, Gallazzi M, Poggi A, Bruno A, Mortara L.

Cancers (Basel). 2019 Apr 1;11(4). pii: E461. doi: 10.3390/cancers11040461. Review.

3.

Violacein Targets the Cytoplasmic Membrane of Bacteria.

Cauz ACG, Carretero GPB, Saraiva GKV, Park P, Mortara L, Cuccovia IM, Brocchi M, Gueiros-Filho FJ.

ACS Infect Dis. 2019 Apr 12;5(4):539-549. doi: 10.1021/acsinfecdis.8b00245. Epub 2019 Feb 12.

PMID:
30693760
4.

Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.

Mortara L, Balza E, Bruno A, Poggi A, Orecchia P, Carnemolla B.

Front Immunol. 2018 Dec 18;9:2905. doi: 10.3389/fimmu.2018.02905. eCollection 2018. Review.

5.

The human RNASET2 protein affects the polarization pattern of human macrophages in vitro.

Scaldaferri D, Bosi A, Fabbri M, Pedrini E, Inforzato A, Valli R, Frattini A, De Vito A, Noonan DM, Taramelli R, Mortara L, Acquati F.

Immunol Lett. 2018 Nov;203:102-111. doi: 10.1016/j.imlet.2018.09.005. Epub 2018 Sep 12.

PMID:
30218741
6.

Tumor Vasculature Targeted TNFα Therapy: Reversion of Microenvironment Anergy and Enhancement of the Anti-tumor Efficiency.

Balza E, Carnemolla B, Orecchia P, Rubartelli A, Poggi A, Mortara L.

Curr Med Chem. 2018 Sep 4. doi: 10.2174/0929867325666180904121118. [Epub ahead of print]

PMID:
30182839
7.

Specific Ion Effects on Zwitterionic Micelles Are Independent of Interfacial Hydration Changes.

Mortara L, Lima FDS, Cuccovia IM, Nazet A, Horinek D, Buchner R, Chaimovich H.

Langmuir. 2018 Sep 18;34(37):11049-11057. doi: 10.1021/acs.langmuir.8b02115. Epub 2018 Sep 4.

PMID:
30126270
8.

Vitamin D Deficiency has a Negative Impact on Cetuximab-Mediated Cellular Cytotoxicity against Human Colon Carcinoma Cells.

Mortara L, Gariboldi MB, Bosi A, Bregni M, Pinotti G, Guasti L, Squizzato A, Noonan DM, Monti E, Campiotti L.

Target Oncol. 2018 Oct;13(5):657-665. doi: 10.1007/s11523-018-0586-x.

PMID:
30090970
9.

Angiogenin and the MMP9-TIMP2 axis are up-regulated in proangiogenic, decidual NK-like cells from patients with colorectal cancer.

Bruno A, Bassani B, D'Urso DG, Pitaku I, Cassinotti E, Pelosi G, Boni L, Dominioni L, Noonan DM, Mortara L, Albini A.

FASEB J. 2018 Oct;32(10):5365-5377. doi: 10.1096/fj.201701103R. Epub 2018 May 15.

PMID:
29763380
10.

Natural Killer Cells from Malignant Pleural Effusion Are Endowed with a Decidual-Like Proangiogenic Polarization.

Bosi A, Zanellato S, Bassani B, Albini A, Musco A, Cattoni M, Desio M, Nardecchia E, D'Urso DG, Imperatori A, Dominioni L, Noonan DM, Mortara L, Bruno A.

J Immunol Res. 2018 Mar 29;2018:2438598. doi: 10.1155/2018/2438598. eCollection 2018.

11.

Acetyl-l-carnitine is an anti-angiogenic agent targeting the VEGFR2 and CXCR4 pathways.

Baci D, Bruno A, Bassani B, Tramacere M, Mortara L, Albini A, Noonan DM.

Cancer Lett. 2018 Aug 10;429:100-116. doi: 10.1016/j.canlet.2018.04.018. Epub 2018 Apr 18.

12.

Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy.

Albini A, Bruno A, Noonan DM, Mortara L.

Front Immunol. 2018 Apr 5;9:527. doi: 10.3389/fimmu.2018.00527. eCollection 2018. Review.

13.

Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders?

Parisi L, Gini E, Baci D, Tremolati M, Fanuli M, Bassani B, Farronato G, Bruno A, Mortara L.

J Immunol Res. 2018 Jan 14;2018:8917804. doi: 10.1155/2018/8917804. eCollection 2018. Review.

14.

Ion dehydration controls adsorption at the micellar interface: hydrotropic ions.

Lima FS, Andrade MFC, Mortara L, Gustavo Dias L, Cuccovia IM, Chaimovich H.

Phys Chem Chem Phys. 2017 Nov 22;19(45):30658-30666. doi: 10.1039/c7cp05283a.

PMID:
29119186
15.

Can the co-dependence of the immune system and angiogenesis facilitate pharmacological targeting of tumours?

Mortara L, Benest AV, Bates DO, Noonan DM.

Curr Opin Pharmacol. 2017 Aug;35:66-74. doi: 10.1016/j.coph.2017.05.009. Epub 2017 Jun 14. Review.

PMID:
28623714
16.

The therapeutic T-cell response induced by tumor delivery of TNF and melphalan is dependent on early triggering of natural killer and dendritic cells.

Balza E, Zanellato S, Poggi A, Reverberi D, Rubartelli A, Mortara L.

Eur J Immunol. 2017 Apr;47(4):743-753. doi: 10.1002/eji.201646544. Epub 2017 Mar 6.

17.

Business model configuration and dynamics for technology commercialization in mature markets.

Flammini S, Arcese G, Lucchetti MC, Mortara L.

Br Food J. 2017;119(11):2340-2358. doi: 10.1108/BFJ-03-2017-0125. Epub 2017 Nov 6.

18.

Ten-year estimated risk of bone fracture in women with differentiated thyroid cancer under TSH-suppressive levothyroxine therapy.

Vera L, Gay S, Campomenosi C, Paolino S, Pera G, Monti E, Mortara L, Seriolo B, Giusti M.

Endokrynol Pol. 2016;67(4):350-8. doi: 10.5603/EP.a2016.0046. Epub 2016 Jul 8.

19.

BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer.

Monti E, Bovero M, Mortara L, Pera G, Zupo S, Gugiatti E, Dono M, Massa B, Ansaldo GL, Massimo G.

Int J Endocrinol. 2015;2015:138734. doi: 10.1155/2015/138734. Epub 2015 Nov 26.

20.

CD56brightCD16- NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation.

Morandi F, Horenstein AL, Chillemi A, Quarona V, Chiesa S, Imperatori A, Zanellato S, Mortara L, Gattorno M, Pistoia V, Malavasi F.

J Immunol. 2015 Aug 1;195(3):965-72. doi: 10.4049/jimmunol.1500591. Epub 2015 Jun 19.

21.

Papillary thyroid cancer in a struma ovarii: a report of a rare case.

Monti E, Mortara L, Zupo S, Dono M, Minuto F, Truini M, Naseri M, Giusti M.

Hormones (Athens). 2015 Jan-Mar;14(1):154-9. doi: 10.14310/horm.2002.1518.

22.

Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis.

Mortara L, Pera G, Monti E, Morbelli S, Minuto F, Sambuceti G, Giusti M.

J Endocrinol Invest. 2014 Nov;37(11):1099-108. doi: 10.1007/s40618-014-0177-3. Epub 2014 Oct 5.

PMID:
25283887
23.

Orchestration of angiogenesis by immune cells.

Bruno A, Pagani A, Pulze L, Albini A, Dallaglio K, Noonan DM, Mortara L.

Front Oncol. 2014 Jul 2;4:131. doi: 10.3389/fonc.2014.00131. eCollection 2014. Review.

24.

Utility of a Liquid Formulation of Levo-thyroxine in Differentiated Thyroid Cancer Patients.

Giusti M, Mortara L, Machello N, Monti E, Pera G, Marenzana M.

Drug Res (Stuttg). 2015 Jun;65(6):332-6. doi: 10.1055/s-0034-1384535. Epub 2014 Jul 14.

PMID:
25020105
25.

Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine.

Mortara L, Orecchia P, Castellani P, Borsi L, Carnemolla B, Balza E.

Cancer Med. 2013 Aug;2(4):478-87. doi: 10.1002/cam4.89. Epub 2013 May 29.

26.

The challenge of prognostic markers in pleural mesothelioma.

Imperatori A, Castiglioni M, Mortara L, Nardecchia E, Rotolo N.

J Thorac Dis. 2013 Jun;5(3):205-6. doi: 10.3978/j.issn.2072-1439.2013.06.12.

27.

Long-term outcome after radioiodine therapy with adjuvant rhTSH treatment: comparison between patients with non-toxic and pre-toxic large multinodular goitre.

Giusti M, Caorsi V, Mortara L, Caputo M, Monti E, Schiavo M, Bagnara MC, Minuto F, Bagnasco M.

Endocrine. 2014 Mar;45(2):221-9. doi: 10.1007/s12020-013-9959-1. Epub 2013 Apr 26.

PMID:
23619962
28.

The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer.

Bruno A, Focaccetti C, Pagani A, Imperatori AS, Spagnoletti M, Rotolo N, Cantelmo AR, Franzi F, Capella C, Ferlazzo G, Mortara L, Albini A, Noonan DM.

Neoplasia. 2013 Feb;15(2):133-42.

29.

Down syndrome, autoimmunity and T regulatory cells.

Pellegrini FP, Marinoni M, Frangione V, Tedeschi A, Gandini V, Ciglia F, Mortara L, Accolla RS, Nespoli L.

Clin Exp Immunol. 2012 Sep;169(3):238-43. doi: 10.1111/j.1365-2249.2012.04610.x.

30.

Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response.

Morandi B, Mortara L, Chiossone L, Accolla RS, Mingari MC, Moretta L, Moretta A, Ferlazzo G.

PLoS One. 2012;7(6):e39170. doi: 10.1371/journal.pone.0039170. Epub 2012 Jun 19.

31.

Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma.

Giusti M, Melle G, Fenocchio M, Mortara L, Cecoli F, Caorsi V, Ferone D, Minuto F, Rasore E.

J Zhejiang Univ Sci B. 2011 Mar;12(3):163-73. doi: 10.1631/jzus.B1000382.

32.

New strategies of mammary cancer vaccination.

Accolla RS, Frangione V, De Lerma Barbaro A, Mortara L.

Breast J. 2010 Sep-Oct;16 Suppl 1:S42-4. doi: 10.1111/j.1524-4741.2010.01003.x.

PMID:
21050309
33.

CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions.

Laurent S, Carrega P, Saverino D, Piccioli P, Camoriano M, Morabito A, Dozin B, Fontana V, Simone R, Mortara L, Mingari MC, Ferlazzo G, Pistillo MP.

Hum Immunol. 2010 Oct;71(10):934-41. doi: 10.1016/j.humimm.2010.07.007. Epub 2010 Aug 1.

PMID:
20650297
34.

CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy.

Frangione V, Mortara L, Castellani P, De Lerma Barbaro A, Accolla RS.

Int J Cancer. 2010 Oct 1;127(7):1614-24. doi: 10.1002/ijc.25183.

35.

Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha.

Balza E, Carnemolla B, Mortara L, Castellani P, Soncini D, Accolla RS, Borsi L.

Int J Cancer. 2010 Jul 1;127(1):101-10. doi: 10.1002/ijc.25018.

36.

Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.

Mortara L, Frangione V, Castellani P, De Lerma Barbaro A, Accolla RS.

Int Immunol. 2009 Jun;21(6):655-65. doi: 10.1093/intimm/dxp034. Epub 2009 Apr 24.

PMID:
19395374
37.

NK cells provide helper signal for CD8+ T cells by inducing the expression of membrane-bound IL-15 on DCs.

Morandi B, Mortara L, Carrega P, Cantoni C, Costa G, Accolla RS, Mingari MC, Ferrini S, Moretta L, Ferlazzo G.

Int Immunol. 2009 May;21(5):599-606. doi: 10.1093/intimm/dxp029. Epub 2009 Mar 26.

PMID:
19325034
38.

Metabolic and cardiovascular risk in patients with a history of differentiated thyroid carcinoma: A case-controlled cohort study.

Giusti M, Mortara L, Degrandi R, Cecoli F, Mussap M, Rodriguez G, Ferone D, Minuto F.

Thyroid Res. 2008 Sep 29;1(1):2. doi: 10.1186/1756-6614-1-2.

39.

Plasmacytoid dendritic cell dynamics and alpha interferon production during Simian immunodeficiency virus infection with a nonpathogenic outcome.

Diop OM, Ploquin MJ, Mortara L, Faye A, Jacquelin B, Kunkel D, Lebon P, Butor C, Hosmalin A, Barré-Sinoussi F, Müller-Trutwin MC.

J Virol. 2008 Jun;82(11):5145-52. doi: 10.1128/JVI.02433-07. Epub 2008 Apr 2.

40.

Inflammation, inflammatory cells and angiogenesis: decisions and indecisions.

Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, Albini A.

Cancer Metastasis Rev. 2008 Mar;27(1):31-40. Review.

PMID:
18087678
41.

Experimental therapeutic approaches to adenocarcinoma: the potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer.

Mortara L, Giuliani L, De Lerma Barbaro A, Accolla RS, Noonan DM.

Surg Oncol. 2007 Dec;16 Suppl 1:S33-6. Epub 2007 Nov 26. Review.

PMID:
18035537
42.

Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.

Mortara L, Balza E, Sassi F, Castellani P, Carnemolla B, De Lerma Barbaro A, Fossati S, Tosi G, Accolla RS, Borsi L.

Eur J Immunol. 2007 Dec;37(12):3381-92.

43.

SIV escape mutants in rhesus macaques vaccinated with NEF-derived lipopeptides and challenged with pathogenic SIVmac251.

Villefroy P, Letourneur F, Coutsinos Z, Mortara L, Beyer C, Gras-Masse H, Guillet JG, Bourgault-Villada I.

Virol J. 2006 Aug 31;3:65.

44.

Inhibition of human T cell leukemia virus type 2 replication by the suppressive action of class II transactivator and nuclear factor Y.

Tosi G, Pilotti E, Mortara L, De Lerma Barbaro A, Casoli C, Accolla RS.

Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12861-6. Epub 2006 Aug 14.

45.

CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.

Mortara L, Castellani P, Meazza R, Tosi G, De Lerma Barbaro A, Procopio FA, Comes A, Zardi L, Ferrini S, Accolla RS.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3435-43.

46.

Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin.

Balza E, Mortara L, Sassi F, Monteghirfo S, Carnemolla B, Castellani P, Neri D, Accolla RS, Zardi L, Borsi L.

Clin Cancer Res. 2006 Apr 15;12(8):2575-82.

47.

Phenotype and function of myeloid dendritic cells derived from African green monkey blood monocytes.

Mortara L, Ploquin MJ, Faye A, Scott-Algara D, Vaslin B, Butor C, Hosmalin A, Barré-Sinoussi F, Diop OM, Müller-Trutwin MC.

J Immunol Methods. 2006 Jan 20;308(1-2):138-55. Epub 2005 Nov 21.

PMID:
16325847
48.

Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS.

Kornfeld C, Ploquin MJ, Pandrea I, Faye A, Onanga R, Apetrei C, Poaty-Mavoungou V, Rouquet P, Estaquier J, Mortara L, Desoutter JF, Butor C, Le Grand R, Roques P, Simon F, Barré-Sinoussi F, Diop OM, Müller-Trutwin MC.

J Clin Invest. 2005 Apr;115(4):1082-91. Epub 2005 Mar 10. Erratum in: J Clin Invest. 2005 May;115(5):1389.

49.

Sequential immunogene therapy with interleukin-12- and interleukin-15-engineered neuroblastoma cells cures metastatic disease in syngeneic mice.

Croce M, Meazza R, Orengo AM, Radić L, De Giovanni B, Gambini C, Carlini B, Pistoia V, Mortara L, Accolla RS, Corrias MV, Ferrini S.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):735-42.

50.

The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in myelomonocytic cells.

De Lerma Barbaro A, Procopio FA, Mortara L, Tosi G, Accolla RS.

Eur J Immunol. 2005 Feb;35(2):603-11.

Supplemental Content

Loading ...
Support Center